Previous 10 | Next 10 |
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10 -5 ) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff 100% (4/4) overall response rate and 75% (3/4) complete response rate ob...
2023-10-02 10:00:06 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off 90% overall response rate observed in relapsed/refractory multipl...
2023-09-25 16:29:57 ET More on Immix Biopharma, Inc. Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Bio...
2023-09-21 12:53:20 ET More on Immix Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix gets FDA orphan drug designation for NXC-...
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The A...
2023-09-19 13:49:41 ET More on Immix Biopharma: Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech ...
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. Plan for NXC-201 to expand into earlier lines of therapy, and beyond the 5% of U.S. hospitals that offer CAR-T today LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ...
2023-09-19 07:00:00 ET Summary In-licensing of NXC-201 transforms Immix into a mid-to-late stage BCMA-targeting CAR-T therapy with a differentiated tolerability profile. First and only CAR-T therapy in clinical development for AL amyloidosis. Recent months have seen the constr...
2023-09-07 10:38:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips A high-ranking official at the Federal Reserve has indicated that the US central bank is planning to maintain its benchmark interest rate during its September policy meeting. This decision co...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...